PTEN-dependent signaling dysregulation is frequently observed in GBM, with mutation occurring in between 5% and 40% of all GBM cases and loss of heterozygosity in 60% to 80% of all cases (Srividya et al., 2011). Here, PTEN is linked to glioblastoma.